All In Biotech

Investigational drug · Phase 2

ROC-101

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "ROC-101"

First trial start

2025

Oct 1, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ROC-101", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Pulmonary Arterial Hypertension (PAH)
  • Pulmonary Hypertension, Interstitial Lung Disease

Approved drugs for the same conditions: High blood pressure (hypertension) · Pulmonary arterial hypertension · Cardiovascular and metabolic · Respiratory

Largest trials

Live from ClinicalTrials.gov: studies naming "ROC-101" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 4 on PubMed

Also in development for Pulmonary Arterial Hypertension (PAH)

  • IKT-001Phase 32 trials

    Inhibikase Therapeutics · Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)

  • REGN13335Phase 21 trial

    Regeneron · Pulmonary Arterial Hypertension (PAH)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.